RESUMO
OBJECTIVE To re-evaluate systematic review/meta-analysis of escitalopram in the treatment of depression， and to provide reference for clinical use of escitalopram. METHODS Retrieved from CNKI， Wanfang database， VIP， SinoMed， PubMed and the Cochrane Library， etc.， systematic review/meta-analysis of escitalopram in the treatment of depression were collected from the construction of the database to May 17， 2022. The literatures were screened according to the inclusion and exclusion criteria， the basic information of the included literatures was extracted， and the methodological quality， reporting quality and evidence quality of the included literatures were evaluated by using AMSTAR 2 scale， PRISMA statement， and GRADE system， respectively. RESULTS A total of 16 systematic reviews/meta-analyses were included. The results of efficacy comparison showed that escitalopram in the treatment of depression was superior to sertraline in improving the total effective rate， and was comparable to paroxetine， duloxetine and fluoxetine in improving cure rate. The results of safety comparison showed that the safety of escitalopram was higher than that of paroxetine and venlafaxine. The overall methodological quality evaluation of AMSTAR 2 scale was low， and all of them were rated as extremely low； main reason was the lack of many key items. PRISMA score was between 12 and 23 points. Among them， there were 5 literatures with scores ＞21 points， and the reports were relatively complete， 10 literatures with scores between 15 and 21 points， and the reports had certain defects， and 1 literature with scores ≤15 points， with serious information missing. The results of the grading of GRADE evidence showed that， of the 160 included outcome indicators， 69 were moderate evidence， 64 were low-level evidence， and 27 were very low-level evidence. CONCLUSIONS The total effective rate of escitalopram in improving depressive patients is not inferior to that of sertraline； compared with paroxetine， escitalopram is safer. However， the evidence level of the above conclusions is low.
RESUMO
@#ObjectiveTo investigate the effect and mechanisms of rostral ventrolateral medulla (RVL) on the pressor response of lateral hypothalamus-perifornical region (LH/PF) in rats.Methods30 healthy Wistar rats were randomly divided into four groups: the phentolamine group; propranolol group; atropine group and glutamate diethyl ester group, saline was as the control in every group. After microinjection of Glu into LH/PF, the blood pressure and heart rate were observed. Then phentolamine, propranolol, atropine and glutamate diethyl ester were microinjected into RVL and the blood pressure and heart rate changes induced by microinjection of Glu were observed again.ResultsMicroinjection of Glu into LH/PF can cause the blood pressure elevating and heart rate accelerating. The pressor response of Glu to excited LH/PF could be attenuated after response of phentolamine, propranolol, atropine and glutamate diethyl ester microinjected into RVL. The blood pressures of phentolamine group; propranolol group; atropine group and glutamate diethyl ester group reduced significantly different from those in the saline control group (P<0.01).ConclusionThe α-,β-,M- and Glu-receptors in the RVL induce the pressor response of LH/PF region.
RESUMO
The percent of N and C composition in spores or sporocarps of different species of two genera of VA mycorrhizal fungi—Gloraus and Sclerocystis were analysed. It was found that culture period effects the percent of N,C and their ratio, although the influences of host and origin of strain of fungi on those appeared to be low. N,C percentage and their ratio in spores or sporocarps were variable among fungal species of a same genus, but difference between two genera was significantly. This technology may serve as a supplementary indicator for classification and identification of VA mycorrhizal fungi.